J0665 — Injection, bupivicaine, not otherwise specified, 0.5 mg
J0665 is a HCPCS Level II code for injection, bupivicaine, not otherwise specified, 0.5 mg. It belongs to the Drugs Administered Other Than Oral Method section. Whether Medicare pays it depends on the coverage rule below.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
Physician fee schedule statusE
Excluded from the physician fee schedule by regulation. Payment, where it exists, comes from another fee schedule (drugs via ASP, supplies via DMEPOS, and so on).
Global period: XXX
Want the dollar amount for your locality? The fee calculator applies your GPCI and the current conversion factor.
The CMS record for J0665
- Long descriptor
- Injection, bupivicaine, not otherwise specified, 0.5 mg
- Short descriptor
- Inj, bupivacaine, nos, 0.5mg
- Added
- July 1, 2023
- BETOS
- O1E
- Pricing indicator
- 51 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Drugs.
Codes adjacent to J0665
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If J0665 is not quite right, the correct code is very often within a few positions of it.
- J0638Injection, canakinumab, 1 mg
- J0640Injection, leucovorin calcium, per 50 mg
- J0641Injection, levoleucovorin, not otherwise specified, 0.5 mg
- J0642Injection, levoleucovorin (khapzory), 0.5 mg
- J0650Injection, levothyroxine sodium, not otherwise specified, 10 mcg
- J0651Injection, levothyroxine sodium (fresenius kabi), not therapeutically equivalent to j0650, 10 mcg
- J0652Injection, levothyroxine sodium (hikma), not therapeutically equivalent to j0650, 10 mcg
- J0654Injection, liothyronine, 1 mcg
- J0666Injection, bupivacaine liposome, 1 mg
- J0668Instillation, bupivacaine and meloxicam, 1 mg/0.03 mg
- J0670Injection, mepivacaine hydrochloride, per 10 ml
- J0675Injection, carboprost tromethamine, 0.1 mg
- J0681Injection, ceftobiprole medocaril sodium, 3 mg
- J0687Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg
- J0688Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg
- J0689Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg
Questions about J0665
What is HCPCS code J0665?
J0665 is a HCPCS Level II code for injection, bupivicaine, not otherwise specified, 0.5 mg. It sits in the Drugs Administered Other Than Oral Method section.
Does Medicare cover J0665?
The CMS HCPCS file marks J0665 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
How is J0665 paid under the physician fee schedule?
J0665 carries PFS status code E. Excluded from the physician fee schedule by regulation. Payment, where it exists, comes from another fee schedule (drugs via ASP, supplies via DMEPOS, and so on).